BGB-283 Deemed Effective in Phase I Study.
In a phase I trial, BGB-283, which targets the RAF family of proteins, was found to be safe and tolerable-and effective-in treating patients with a variety of solid tumors harboring mutations in BRAF, KRAS, and NRAS.